| Ytd | -81.51% | |
| 1y | -75.60% |
| Open | 0.99 | Prev Close | 0.98 | Low | 0.98 | High | 1.05 | Mkt Cap | 178.83M |
| Vol | 3.67M | Avg Vol | 4.14M | EPS | -0.39 | P/E | N/A | Forward P/E | -10.86 |
| Beta | 1.30 | Short Ratio | 12.39 | Inst. Own | 88.00% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-05 | 50-d Avg | 1.89 | 200-d Avg | 3.55 | 1yr Est | 13.64 |
CMPX News
Wall Street analysts downgraded Rollins, Yum Brands, Alkami Technology, VICI Properties and Safehold
Craig-Hallum analyst Albert Lowe maintains Compass Therapeutics (NASDAQ:CMPX) with a Buy and lowe
Compass Therapeutics faces a major setback after tovecimig failed to show an overall survival benefi
Analysts downgraded Accelerant, Autoliv, Compass Therapeutics, Wave Life Sciences and PG&E; pric
Citizens analyst Reni J. Benjamin maintains Compass Therapeutics (NASDAQ:CMPX) with a Market Outp
Guggenheim analyst Michael Schmidt maintains Compass Therapeutics (NASDAQ:CMPX) with a Buy and lo
Wedbush analyst Robert Driscoll downgrades Compass Therapeutics (NASDAQ:CMPX) from Outperform to
HC Wainwright & Co. analyst Joseph Pantginis maintains Compass Therapeutics (NASDAQ:CMPX) wit
U.S. stocks were mixed: Nasdaq and S&P 500 rose while the Dow fell; communication services gaine
Compass Therapeutics, Inc. (NASDAQ:CMPX) shares are trading lower on Tuesday as the FDA feedback rai
Compass Therapeutics shares plunge after FDA seeks a survival-benefit trial before tovecimig’s FDA m
Gainers Jaguar Health (NASDAQ:JAGX) stock increased by 304.5% to $10.8 during Tuesday's regular
U.S. stocks rose Tuesday: Dow +0.24%, Nasdaq +0.39%, S&P 500 +0.18%. Communication services led;
BOSTON, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-sta
Piper Sandler analyst Biren Amin maintains Compass Therapeutics (NASDAQ:CMPX) with a Overweight a
Compass Therapeutics (NASDAQ:CMPX) reported quarterly losses of $(0.13) per share which missed the a
The Company expects feedback from the FDA this quarter regarding the COMPANION-002 Phase 2/3 data fo
Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical compa
BOSTON, July 17, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stag
Compass Therapeutics is rated Buy, with risk/reward favoring upside after a sharp post-data selloff.
Compass Therapeutics, Inc. (CMPX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference
Compass Therapeutics NASDAQ: CMPX Chief Executive Officer Tom Schuetz said the company is preparing
BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage
CTX-8371, a novel dual checkpoint blocker that simultaneously targets the programmed death receptor
BOSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutic
NEW YORK, May 21, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors
NEW YORK, May 19, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of invest
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutic
NEW YORK, May 14, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors
NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of invest
BOSTON, May 12, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage
NEW YORK, May 7, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors o
Compass Therapeutics (NASDAQ:CMPX) reported quarterly losses of $(0.10) per share which met the anal
As recently announced, tovecimig (DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel
Canaccord Genuity analyst John Newman maintains Compass Therapeutics (NASDAQ:CMPX) with a Buy and
Citizens analyst Reni J. Benjamin reiterates Compass Therapeutics (NASDAQ:CMPX) with a Market Out
HC Wainwright & Co. analyst Joseph Pantginis reiterates Compass Therapeutics (NASDAQ:CMPX) wi
U.S. stocks trade lower on Monday, with Dow falling 0.1%. Verizon beats Q1 earnings, raises FY26 gui
US stocks mixed on Monday, Nasdaq falls 0.56% while Dow gains 0.06%. Energy shares up 1%. Domino'
U.S. stock futures mixed with Dow futures down 0.1%. Domino's Pizza misses earnings expectations
QCOM: 13% | OpenAI Eyes 'AI Agent' Smartphone With Qualcomm And MediaTek, Targets App-Free E
Organon & Co (OGN) jumped 14.8% in pre-market trading as Sun Pharma agreed to acquire the compan
